BioAegis Therapeutics

BioAegis Therapeutics is pioneering a non-immunosuppressive approach to treating inflammatory diseases through its platform based on the recombinant human protein plasma gelsolin (pGSN). The company is clinical-stage, with a pipeline targeting both acute and chronic conditions driven by inflammation, supported by a strong intellectual property portfolio licensed from Harvard and other institutions. Recent milestones include securing a second FDA Fast Track designation in August 2025 for treating inflammasome-driven decompensation sickness, highlighting regulatory interest in its novel mechanism.

Platform built around recombinant human plasma gelsolin (rhu-pGSN), a natural immune regulator protein that modulates inflammation without immunosuppression by neutralizing inflammatory triggers and enhancing immune cell function.

BioAegis competes in the vast anti-inflammatory therapeutics market against large-cap biopharma companies with cytokine inhibitors (e.g., anti-TNF, anti-IL-6) and a growing number of biotechs targeting novel pathways. Its key differentiation is a non-immunosuppressive, pro-resolutive mechanism that may avoid the infection risks associated with many immunomodulators.